Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

Drug transporters are increasingly recognized to be important to drug disposition and
response. P‐glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of …

In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most
recent advances in the drug/dose optimization of TAC taking into account specific clinical …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

Cyclosporine and tacrolimus are immunosuppressive drugs largely used in renal
transplantation. They are characterized by a wide inter-individual variability in their …